New York State Common Retirement Fund decreased its stake in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 23.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,183 shares of the specialty pharmaceutical company’s stock after selling 9,216 shares during the quarter. New York State Common Retirement Fund owned 0.11% of Paratek Pharmaceuticals worth $758,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. C WorldWide Group Holding A S lifted its stake in Paratek Pharmaceuticals by 46.8% in the third quarter. C WorldWide Group Holding A S now owns 645,100 shares of the specialty pharmaceutical company’s stock valued at $16,192,000 after buying an additional 205,700 shares during the period. Russell Investments Group Ltd. lifted its stake in Paratek Pharmaceuticals by 481.5% in the second quarter. Russell Investments Group Ltd. now owns 63,787 shares of the specialty pharmaceutical company’s stock valued at $1,538,000 after buying an additional 52,818 shares during the period. State Street Corp lifted its stake in Paratek Pharmaceuticals by 112.3% in the second quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock valued at $14,850,000 after buying an additional 325,856 shares during the period. Alliancebernstein L.P. lifted its stake in Paratek Pharmaceuticals by 71.3% in the second quarter. Alliancebernstein L.P. now owns 20,900 shares of the specialty pharmaceutical company’s stock valued at $504,000 after buying an additional 8,700 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Paratek Pharmaceuticals by 40.9% in the second quarter. Goldman Sachs Group Inc. now owns 131,723 shares of the specialty pharmaceutical company’s stock valued at $3,175,000 after buying an additional 38,222 shares during the period. 84.30% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts have issued reports on PRTK shares. ValuEngine downgraded Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Robert W. Baird restated a “buy” rating and issued a $40.00 price target on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. Cantor Fitzgerald set a $50.00 price target on Paratek Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. Guggenheim started coverage on Paratek Pharmaceuticals in a report on Tuesday, October 24th. They issued a “buy” rating and a $44.00 price target for the company. Finally, Zacks Investment Research downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Paratek Pharmaceuticals presently has an average rating of “Buy” and an average price target of $40.00.

Shares of Paratek Pharmaceuticals Inc (PRTK) opened at $18.77 on Friday. Paratek Pharmaceuticals Inc has a fifty-two week low of $13.95 and a fifty-two week high of $29.00. The stock has a market capitalization of $526.69, a PE ratio of -5.03 and a beta of 0.70. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49.

ILLEGAL ACTIVITY NOTICE: “New York State Common Retirement Fund Has $758,000 Holdings in Paratek Pharmaceuticals Inc (PRTK)” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/new-york-state-common-retirement-fund-has-758000-holdings-in-paratek-pharmaceuticals-inc-prtk/1796744.html.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.